Alcon today announced the launch of ILEVRO™ Suspension, a new once-daily treatment option for pain and inflammation associated with cataract surgery. In two double masked, randomized clinical trials, ILEVRO™ Suspension demonstrated superior clinical efficacy compared to its vehicle.
In the studies, patients treated with ILEVRO™ Suspension were less likely to have ocular pain and measurable signs of inflammation (cells and flare) at the end of treatment than those treated with its vehicle.
“We are committed to developing products that continue to improve patient care,” said Gary Menichini, Vice President and General Manager, U.S. Pharmaceuticals. “This launch represents the dedication of the R&D team to engineer an efficacious, innovative formulation with a reduced dosing regimen.”
Patients administered ILEVRO™ Suspension experienced superior outcomes when compared to those on vehicle in the following areas:
- Inflammation resolved at day 14 in 65 percent of ILEVRO™ Suspension patients vs. 32 percent of patients on vehicle
- Pain resolution rates in ILEVRO™ Suspension treated patients were 86 percent compared to 46 percent of patients on vehicle
The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These reactions occurred in approximately 5 to 10% of patients.
“Effective management of pain and inflammation associated with cataract surgery is a priority for me,” said Stephen Lane, MD. “I am confident that this highly effective option, with its innovative formulation, will benefit my patients.”
For more information on ILEVRO™ Suspension visit alcon.com and refer to accompanying full prescribing information.